Results 221 to 230 of about 60,007 (250)

Pharmacotherapy of Duchenne Muscular Dystrophy

2019
Drug development and pharmacotherapy of rare pediatric diseases have significantly expanded over the last decade, in part due to incentives and financial support provided by governments, regulators, and nonprofit foundations. Duchenne muscular dystrophy (DMD) is among the most common rare pediatric disorders, and clinical trials of therapeutic ...
openaire   +2 more sources

Delayed Diagnosis in Duchenne Muscular Dystrophy: Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)

Journal of Pediatrics, 2009
Paul A Romitti, Katherine Mathews, Timothy M Miller   +2 more
exaly  

Duchenne Muscular Dystrophy

Pediatrics In Review, 2006
openaire   +2 more sources

miRNAs as serum biomarkers for Duchenne muscular dystrophy

EMBO Molecular Medicine, 2011
Davide Cacchiarelli, Ivano Legnini, Adele D'amico   +2 more
exaly  

Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy

Journal of Cell Biology, 2014
Akanchha Kesari, Kanneboyina Nagaraju, Mamta Giri   +2 more
exaly  

Prevention of Pulmonary Morbidity for Patients With Duchenne Muscular Dystrophy

Chest, 1997
John R Bach, Yuka Ishikawa
exaly  

Pulmonary Endpoints in Duchenne Muscular Dystrophy. A Workshop Summary

American Journal of Respiratory and Critical Care Medicine, 2017
Hemant Sawnani, David J Birnkrant, Erik Henricson   +2 more
exaly  

Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study

Lancet, The, 2018
Eric P Hoffman, Heather Gordish-Dressman, Jean K Mah   +2 more
exaly  

Disparities in the diagnostic process of Duchenne and Becker muscular dystrophy

Genetics in Medicine, 2011
Jennifer G Andrews, Christopher M Cunniff   +1 more
exaly  

Cognitive and Neurobehavioral Profile in Boys With Duchenne Muscular Dystrophy

Journal of Child Neurology, 2015
Rudaina Banihani, Sharon Smile, Grace Yoon   +2 more
exaly